Astrazeneca plc, of London, said The Lancet Respiratory Medicine published safety and efficacy data from a phase IIa study evaluating monoclonal antibody benralizumab in patients with chronic obstructive pulmonary disease. The study, conducted by its Medimmune arm, evaluated the product in 101 adults, but did not meet the primary endpoint, as benralizumab did not reduce the acute exacerbation rate compared with placebo. It did, however, demonstrate clinically significant improvements in lung function in the overall population, and the ability to reduce exacerbations and improve other symptoms in certain patient groups, such as those who had higher baseline levels of eosinophils in their blood. Benralizumab is an anti-interleukin-5 receptor alpha monoclonal antibody that depletes blood and sputum eosinophils.
Eisai Co. Ltd., of Tokyo, said a new subgroup analysis showed significant improvement in progression-free survival with lenvatinib in radioiodine-refractory differentiated thyroid cancer compared with placebo, 18.3 months vs. 3.6 months. Results are being presented at the European Thyroid Association 38th Annual Meeting.
Teva Pharmaceutical Industries Ltd., of Jerusalem, successfully completed a phase III program for Reslizumab, an anti-IL5 monoclonal antibody, in patients with uncontrolled moderate to severe asthma with elevated eosinophils. Data demonstrated the treatment resulted in significant improvement in lung function and asthma control measures and showed a safety profile comparable to placebo. Improvement was measured by overall change in Forced Expiratory Volume in 1 second.